<unk>  is indicated for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
Mobocertinib
Lestaurtinib
Selpercatinib
Upadacitinib
Osimertinib
Brigatinib
Abrocitinib
Baricitinib